I didn't do my research well enough. Turns out subsequent to...

First 104 Last

Share
Profile

Follow
Mikesmith1981

339 Posts.

62

21/06/24

09:17

Post #: 74418754
Share

Originally posted by Rubiconis: ↑

I don't follow cricket so not sure what you blabbing about there.

Anyway, I am pretty sure at the time, the performance rights, way out of the money, were cancelled. They lapsed, without a swap for DYL shares. The agreement made an allowance for it, concurrent with schedule 2. From memory, there was a 2-part section for the treatment of lapsed unlisted options. But, I may be wrong.

Regardless, your contention that it was the lack of financial incentive that led to RH's poor performance is disturbing. Especially considering that over time he has sold down his once substantial private holding to essentially zero.

And further, while you say to this forum that the stock at these prices is cheap and a great buy, your fearless leader has not bought a single share, and has no plans to do so. What does that tell you? Can you think why a director would sell down his entire holding? And then refuse to buy, even at all time lows?

Doesn't take a genius to figure it out. It's called... "a permitless uranium project, under a uranium mining ban, with Labour-Green alliance about to get re-elected again". RH is many things, but stupid, he ain't.

Expand

I didn't do my research well enough. Turns out subsequent to last annual report he added 1m shares

https://www.marketindex.com.au/asx/directors/richard-homsany

Last edited by Mikesmith1981: 21/06/24

TOE Price at posting: 35.0¢ Sentiment: Hold Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

PL3

Patagonia looks to raise $2.15M for South American exploration and development

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

There are more pages in this discussion • 242 more messages in this thread...

First 104 Last

Add TOE (ASX) to my watchlist

(20min delay)
Last 33.0¢		Change -0.010(2.94%)		Mkt cap ! $39.69M

Open	High	Low	Value	Volume
33.0¢	34.0¢	33.0¢	$37.83K	113.1K

Buyers (Bids)

No.	Vol.	Price($)
1	10162	33.0¢

Sellers (Offers)

Price($)	Vol.	No.
35.0¢	86946	6

View Market Depth

No.	Vol.	Price($)
1	10162	0.330
1	4000	0.325
1	20000	0.320
2	47000	0.315
4	24456	0.310

Price($)	Vol.	No.
0.350	86946	6
0.355	35646	2
0.360	2000	1
0.370	2000	1
0.375	28000	2

Last trade - 16.10pm 09/07/2024 (20 minute delay)

TOE (ASX) Chart

I didn't do my research well enough. Turns out subsequent to...

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I didn't do my research well enough. Turns out subsequent to...

Top Stories

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News